Xilio Therapeutics Inc [NASDAQ: XLO] gained 2.96% on the last trading session, reaching $0.73 price per share at the time.
If compared to the average trading volume of 3.70M shares, XLO reached a trading volume of 2944303 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Xilio Therapeutics Inc [XLO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for XLO shares is $4.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on XLO stock is a recommendation set at 1.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Chardan Capital Markets have made an estimate for Xilio Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 21, 2022. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on January 10, 2022, representing the official price target for Xilio Therapeutics Inc stock. Previously, the target price had yet another raise to $31, while Raymond James analysts kept a Outperform rating on XLO stock.
The Average True Range (ATR) for Xilio Therapeutics Inc is set at 0.06, with the Price to Sales ratio for XLO stock in the period of the last 12 months amounting to 4.08. The Price to Book ratio for the last quarter was 3.54, with the Price to Cash per share for the same quarter was set at 1.72. Price to Free Cash Flow for XLO in the course of the last twelve months was 1.80 with Quick ratio for the last quarter at 1.96.
Trading performance analysis for XLO stock
Xilio Therapeutics Inc [XLO] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.19. With this latest performance, XLO shares gained by 10.51% in over the last four-week period, additionally sinking by -43.33% over the last 6 months – not to mention a drop of -39.59% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for XLO stock in for the last two-week period is set at 47.61, with the RSI for the last a single of trading hit 48.39, and the three-weeks RSI is set at 47.17 for Xilio Therapeutics Inc [XLO]. The present Moving Average for the last 50 days of trading for this stock 0.7652, while it was recorded at 0.7041 for the last single week of trading, and 0.8890 for the last 200 days.
Xilio Therapeutics Inc [XLO]: A deeper dive into fundamental analysis
Xilio Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.96 and a Current Ratio set at 1.96.
Xilio Therapeutics Inc [XLO]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for XLO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Xilio Therapeutics Inc go to -4.67%.
An analysis of Institutional ownership at Xilio Therapeutics Inc [XLO]
The top three institutional holders of XLO stocks are: BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC with ownership of 3.79 million shares, which is approximately 13.5618%. ROCK SPRINGS CAPITAL MANAGEMENT LP, holding 3.0 million shares of the stock with an approximate value of $$2.85 million in XLO stocks shares; and ROCK SPRINGS CAPITAL MANAGEMENT LP, currently with $$1.37 million in XLO stock with ownership which is approximately 5.1641%.
